Skip to main content
. 2022 Mar 15;14(3):210. doi: 10.3390/toxins14030210

Table 1.

Selection of SGLT2 inhibitors and their pharmacokinetic properties in humans.

SGLTi Human SGLT1 (IC50 nM) Human SGLT2 (IC50 nM) Protein Binding
(%)		 t1/2
(h)		 F
(%)		 fe
(%)		 Refs.
canagliflozin 684 4.4 98 11–13 65 <1% [4,5]
dapagliflozin 803 1.6 91 12.2 78 <2% [4]
empagliflozin 8300 3.1 86 11.4–12.4 60–78 11–29 [4,6,7,8]
ertugliflozin 1960 0.9 94 11–18 100 1.5% [9,10]
ipragliflozin 2329 8.9 96 10–13 90 <1% [4,11,12]
tofogliflozin 8444 2.9 83 6.8 97.5 76% [4,13]

Abbreviations: t1/2—terminal half-life in plasma; F—bioavailability; fe—fraction of dose that was excreted unchanged in urine; IC50—half maximal inhibitory concentration.